Spero Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Spero Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2023.
  • Spero Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $108M, a 6.02% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $108M -$6.91M -6.02% Dec 31, 2023 10-K 2024-03-13
Q4 2022 $115M +$12.3M +12.1% Dec 31, 2022 10-K 2024-03-13
Q4 2021 $102M +$27.4M +36.5% Dec 31, 2021 10-K 2024-03-13
Q4 2020 $75M +$23.1M +44.4% Dec 31, 2020 10-K 2023-03-30
Q4 2019 $52M +$17.8M +52.3% Dec 31, 2019 10-K 2022-03-31
Q4 2018 $34.1M +$9.62M +39.2% Dec 31, 2018 10-K 2021-03-11
Q4 2017 $24.5M +$7.37M +43% Dec 31, 2017 10-K 2020-03-16
Q4 2016 $17.2M +$11M +179% Dec 31, 2016 10-K 2019-03-14
Q4 2015 $6.16M Dec 31, 2015 10-K 2018-04-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.